Shrewd - Enquiry Form

Disclaimer: Any person accessing the email and considering potential investment opportunities featured in the email should make their own commercial assessment after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. This opportunity is only suitable for high net worth or self-sophisticated investors as defined; you will have an annual income in excess of £100K. Have net assets in excess of £250K beyond your pension fund assets and your private residence. You have been a Director of a company turning over at least £1 million within the last two years. You have made more than one investment in an unlisted company in the previous two years. You have been a member of a network or syndicate of business angels for at least six months. You have worked in the past two years in a professional capacity in the private equity sector or in the provision of finance for small and medium enterprises..

Company: Shrewd

First Floor 690 Great West Road, Osterley Village, Isleworth, England, TW7 4PU

Privacy Notice

Company No. 14416890 :: Registered in England and Wales

Registered Address: First Floor 690 Great West Road, Osterley Village, Isleworth, England, TW7 4PU

Please complete the form to obtain further details

Leading Innovation in Cancer Screening

Frontier Diagnostics are advancing the early detection and monitoring of cancer through scientific expertise and AI-powered laboratory technology.

£10,000 Minimum Investment

Now in the 3rd year of trading and taking orders worldwide delve deeper this exciting groundbreaking venture.

Secure your EIS-approved investment guide now and discover how your contribution can reshape the landscape of cancer care.

Investment Highlights:

Frontier Diagnostics is driving the next generation of cancer screening through scientific expertise and clinical innovation.

Our mission is simple - to transform how cancer is detected, diagnosed, and monitored through cutting-edge laboratory technology and AI-powered blood tests.

__________________________________________________

EIS Benefits:

• Receive up to 30% income tax relief on investment.

• Defer or eliminate capital gains on qualifying shares along with loss relief

• Benefit from inheritance tax exemption after holding two years

Outstanding opportunity to support a UK-based biotech company focused on improving and potentially extending lives through early detection and diagnosis.